Agenus Stock Soars 64.16% on $141M Zydus Cancer Drug Deal

Agenus's stock surged by 64.16% in pre-market trading on June 3, 2025, marking a significant rise that has caught the attention of investors and analysts alike.

Agenus has recently secured a substantial deal worth $141 million with Zydus, focusing on the development and manufacturing of cancer drugs and facilities. This strategic partnership is expected to bolster Agenus's pipeline and enhance its capabilities in the oncology sector.

The collaboration with Zydus is part of Agenus's broader strategy to expand its presence in the biopharmaceutical industry. By leveraging Zydus's expertise and resources, Agenus aims to accelerate the development of innovative cancer treatments, potentially leading to new therapeutic options for patients.

This deal comes at a time when Agenus is actively pursuing various initiatives to strengthen its market position. The company has been focusing on advancing its clinical programs and exploring new partnerships to drive growth and innovation in the biotech sector.

Investors are closely monitoring Agenus's progress, as the company's strategic moves and partnerships are seen as key drivers for its future success. The recent surge in stock price reflects the market's optimism about Agenus's potential to deliver groundbreaking cancer therapies and achieve significant milestones in the coming years.